NCT02099539 2024-09-26QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple MyelomaAltor BioSciencePhase 1 Terminated19 enrolled 22 charts
NCT02890758 2023-02-21Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803Case Comprehensive Cancer CenterPhase 1 Completed14 enrolled
NCT03003728 2020-07-102015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)University of ArkansasPhase 2 Withdrawn